Small ankyrin 1 (sANK1) promotes docetaxel resistance in castration‐resistant prostate cancer cells by enhancing oxidative phosphorylation

Docetaxel (DTX) plays an important role in treating advanced prostate cancer (PCa). However, nearly all patients receiving DTX therapy ultimately progress to DTX resistance. How to address DTX resistance in PCa remains a key challenge for all urologists. Small ankyrin 1 (sAnk1) is an integral membra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, Qin, Haixiang, Ding, Meng, Ji, Changwei, Chen, Wei, Diao, Wenli, Yin, Haoli, Chen, Mengxia, Gan, Weidong, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900087/
https://www.ncbi.nlm.nih.gov/pubmed/36508323
http://dx.doi.org/10.1002/2211-5463.13535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900087/
https://www.ncbi.nlm.nih.gov/pubmed/36508323
http://dx.doi.org/10.1002/2211-5463.13535

Ejemplares similares